Quantitative analysis and pharmacokinetic study of a novel diarylurea EGFR inhibitor (ZCJ14) in rat plasma using a validated LC-MS/MS method

Quantitative analysis and pharmacokinetic study of a novel diarylurea EGFR inhibitor (ZCJ14) in rat plasma using a validated LC-MS/MS method

1-(4-(Pyrrolidin-1-yl-methyl)phenyl)-3-(4-((3-(trifluoromethyl) phenyl)amino)quinazolin-6-yl)urea (ZCJ14), a novel epidermal growth factor receptor (EGFR) inhibitor, with diarylurea moiety, displays anticancer effect. In the present study, an LCMS/MS method was established to determine the concentra...

Full description

Bibliographic Details
Main Authors: Zuo Sai-Jie, Cheng Xiao-Liang, Liu Dong-Zheng, Feng Wei-Yi, Cao Yong-Xiao, Zhang San-Qi
Format: Article
Language:English
Published: Sciendo 2021-09-01
Series:Acta Pharmaceutica
Subjects:
zcj14
epidermal growth factor receptor inhibitor
lc-ms/ms
pharmacokinetics
bioavailability
Online Access:https://doi.org/10.2478/acph-2021-0024

Internet

https://doi.org/10.2478/acph-2021-0024

Similar Items